Arrowhead Pharmaceuticals（股票代码：ARWR）宣布，该公司计划在2026年年底之前，利用一张优先审评券（Priority Review Voucher），为旗下药物Plozasiran提交针对重度高甘油三酯血症（Severe Hypertriglyceridemia）的补充新药申请（sNDA）。这一举动显示出该公司正加速推进其关键管线的监管审批进程。通过使用这一宝贵资源，Arrowhead希望缩短审评周期，使治疗方案更快惠及患者。
Arrowhead Pharmaceuticals（股票代码：ARWR）宣布，该公司计划在2026年年底之前，利用一张优先审评券（Priority Review Voucher），为旗下药物Plozasiran提交针对重度高甘油三酯血症（Severe Hypertriglyceridemia）的补充新药申请（sNDA）。这一举动显示出该公司正加速推进其关键管线的监管审批进程。通过使用这一宝贵资源，Arrowhead希望缩短审评周期，使治疗方案更快惠及患者。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.